Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kosuke Yusa

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Blood|August 25, 2017
Molecular synergy underlies the co-occurrence patterns and phenotype of <i>NPM1</i>-mutant acute myeloid leukemiaOliver M Dovey, Jonathan L Cooper, Annalisa Mupo, et al.
Blood|December 21, 2011
The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiationAnastasia Nijnik, Simon Clare, Christine Hale, et al.
Molecular Cancer Therapeutics|March 12, 2026
A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinomaShunsuke Kawahara, Mana Taki, Junzo Hamanishi, et al.
Journal for Immunotherapy of Cancer|June 20, 2025
HVJ-E links Apolipoprotein d to antitumor effectsAiri Ishibashi, Noriko Ohta, Yuko Uegaki, et al.
Cell Stem Cell|November 28, 2017
Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular ReprogrammingTyson Ruetz, Ulrich Pfisterer, Bruno Di Stefano, et al.
Cancer Science|September 16, 2025
Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate CancerMasaru Tani, Koji Hatano, Yu Ishizuya, et al.
Nature Communications|May 18, 2019
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screeningGabriele Picco, Elisabeth D Chen, Luz Garcia Alonso, et al.
Oncogene|October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitorsShanade Dunn, Cath Eberlein, Jason Yu, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Nature|October 14, 2011
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cellsKosuke Yusa, S Tamir Rashid, Helene Strick-Marchand, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Blood|August 25, 2017
Molecular synergy underlies the co-occurrence patterns and phenotype of <i>NPM1</i>-mutant acute myeloid leukemiaOliver M Dovey, Jonathan L Cooper, Annalisa Mupo, et al.
Blood|December 21, 2011
The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiationAnastasia Nijnik, Simon Clare, Christine Hale, et al.
Molecular Cancer Therapeutics|March 12, 2026
A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinomaShunsuke Kawahara, Mana Taki, Junzo Hamanishi, et al.
Journal for Immunotherapy of Cancer|June 20, 2025
HVJ-E links Apolipoprotein d to antitumor effectsAiri Ishibashi, Noriko Ohta, Yuko Uegaki, et al.
Cell Stem Cell|November 28, 2017
Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular ReprogrammingTyson Ruetz, Ulrich Pfisterer, Bruno Di Stefano, et al.
Cancer Science|September 16, 2025
Development of a Synthetic Lethality-Based Combination Therapy Using LIG1 and PARP Inhibitors for Prostate CancerMasaru Tani, Koji Hatano, Yu Ishizuya, et al.
Nature Communications|May 18, 2019
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screeningGabriele Picco, Elisabeth D Chen, Luz Garcia Alonso, et al.
Oncogene|October 14, 2022
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitorsShanade Dunn, Cath Eberlein, Jason Yu, et al.
Nature Communications|May 12, 2018
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceStephen J Pettitt, Dragomir B Krastev, Inger Brandsma, et al.
Nature|October 14, 2011
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cellsKosuke Yusa, S Tamir Rashid, Helene Strick-Marchand, et al.
Pageof 9